Form 4: TransDigm CEO Lisman Granted Performance-Based Stock Options
Insider Transaction Report
TransDigm Group's President and CEO, Michael Lisman, was granted 79,603 stock options with an exercise price of $1,291.97, exercisable over future years subject to performance targets.
Summary
- Michael Lisman, President & CEO of TransDigm Group INC (TDG), was granted a total of 79,603 stock options.
- The options have an exercise price of $1,291.97 per share.
- A grant of 75,696 options becomes exercisable at 20% per year over five years, starting September 30, 2026, contingent on achieving annual operating performance targets.
- An additional grant of 3,907 options becomes exercisable at 80% in 2026 and 20% in 2027, also subject to annual operating performance targets.
- All granted options have an expiration date of November 4, 2035.
- The transaction date for these grants was November 4, 2025.
Sentiment
Score: 6
Explanation: The grant of performance-based stock options to the CEO is generally viewed as a positive for aligning management incentives with shareholder value creation, though it is a routine compensation event rather than a significant operational or financial announcement.
Positives
- The grant of stock options aligns the interests of President & CEO Michael Lisman with those of shareholders, as the value of the options is tied to the company's stock performance.
- The performance-based vesting conditions incentivize management to achieve specific annual operating targets, potentially driving company growth and profitability.
Risks
- The exercisability of the stock options is subject to the achievement of annual operating performance targets, meaning the options may not fully vest if targets are not met.
Future Outlook
The future outlook indicates that a significant portion of the CEO's compensation is tied to the company's future operating performance, with options vesting over the next several years (2026-2031) contingent on achieving specific annual targets.
Industry Context
This Form 4 filing is a routine disclosure of an insider equity grant, common in publicly traded companies as part of executive compensation packages. It reflects the company's strategy to incentivize its top leadership through performance-based equity awards, a standard practice across various industries to align management and shareholder interests.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Michael Lisman granted a Power of Attorney to a group of individuals (Armani Vadiee, Rachel Quinlan, Lisa Tortora-French, and Adrienne McFaye) to execute and file Forms ID, 3, 4, and 5 on his behalf, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. | 10/22/2025 | This streamlines the process for timely and accurate SEC filings related to insider transactions, enhancing compliance efficiency. |
Related Party Transactions
- The grant of stock options to Michael Lisman, the President & CEO, constitutes a related party transaction as it involves compensation from the company to a key executive. This is a standard form of executive compensation.
Stakeholder Impact
- Shareholders: The performance-based vesting of options aims to align the CEO's incentives with shareholder value creation, potentially leading to improved company performance.
- Management: The CEO's compensation package is enhanced with long-term equity incentives.
Next Steps
- Michael Lisman will continue to serve as President & CEO of TransDigm Group INC.
- The granted stock options will become exercisable in tranches over the next five years, subject to the achievement of annual operating performance targets.
Key Dates
| Date | Description |
|---|---|
| 10/22/2025 | Date Michael Lisman signed the Power of Attorney. |
| 11/04/2025 | Date of the stock option grant transaction. |
| 11/06/2025 | Date the Form 4 was signed by Rachel L. Quinlan as attorney-in-fact. |
| 2026 | Year when 80% of the 3,907 options become exercisable. |
| 09/30/2026 | Beginning date for the 20% annual exercisability of 75,696 options over five years. |
| 11/04/2026 | First date of exercisability for the 75,696 stock options. |
| 2027 | Year when 20% of the 3,907 options become exercisable. |
| 11/04/2035 | Expiration date for all granted stock options. |
Keywords
TransDigm Group, TDG, Michael Lisman, stock options, insider transaction, Form 4, CEO compensation, equity grant, performance targets
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.